Coherus Oncology to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Coherus Oncology (NASDAQ:CHRS) announced its participation in three upcoming investor conferences in September and October 2025. The company will present at the Baird 2025 Global Healthcare Conference on September 9, the H.C. Wainwright Global Investment Conference on September 10, and the UBS Virtual Oncology Day on October 1, 2025.

All presentations will be accessible through webcast links on the company's investor relations website, with replays available for 30 days. Investors interested in one-on-one meetings with management should contact their respective bank representatives.

News Market Reaction – CHRS

+5.88%

8 alerts

+5.88% News Effect

+12.1% Peak in 23 hr 44 min

+$9M Valuation Impact

$162M Market Cap

0.8x Rel. Volume

On the day this news was published, CHRS gained 5.88%, reflecting a notable positive market reaction. Argus tracked a peak move of +12.1% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $9M to the company's valuation, bringing the market cap to $162M at that time.

Data tracked by StockTitan Argus on the day of publication.

REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences:

• Baird 2025 Global Healthcare Conference in New York, NY on Tuesday, September 9, 2025, at 1:25 p.m. Eastern Daylight Time / 10:25 a.m. Pacific Daylight Time
• H.C. Wainwright 27^th Annual Global Investment Conference in New York, NY on Wednesday, September 10, 2025, at 11:00 a.m. Eastern Daylight Time / 8:00 a.m. Pacific Daylight Time
• UBS Virtual Oncology Day takes place virtually on Wednesday, October 1, 2025, at 1:00 p.m. Eastern Daylight Time / 10:00 a.m. Pacific Daylight Time
  

The presentations will be accessible via webcast links on the Investor Events section of the Coherus website: https://investors.coherus.com/events-presentations. Replays of the presentations will be available for 30 days.

If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective bank representative.

Disclosure Information

Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. 

About Coherus
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI^® (toripalimab-tpzi), growing revenues and a promising proprietary pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. The Company’s strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its partners, driving sales multiples and synergies from proprietary combinations.

Coherus’ immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in multiple Phase 1/2 and Phase 2 studies in patients with advanced solid tumors, including NSCLC and HCC. CHS-114 is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b studies in patients with advanced solid tumors, including HNSCC, gastric cancer, and esophageal cancer.

For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.

Coherus Contact Information
Investors:
Jodi Sievers
VP, Investor Relations & Corporate Communications
IR@coherus.com

FAQ

When is Coherus Oncology (CHRS) presenting at the Baird Global Healthcare Conference 2025?

Coherus will present at the Baird Conference on Tuesday, September 9, 2025, at 1:25 p.m. EDT.

How can investors access Coherus Oncology's (CHRS) conference presentations?

Investors can access the presentations via webcast links on the Investor Events section of Coherus website at investors.coherus.com/events-presentations. Replays will be available for 30 days.

What investor conferences is Coherus Oncology (CHRS) attending in Fall 2025?

Coherus is attending three conferences: Baird Global Healthcare Conference (Sept 9), H.C. Wainwright Global Investment Conference (Sept 10), and UBS Virtual Oncology Day (Oct 1, 2025).

How can investors schedule one-on-one meetings with Coherus Oncology (CHRS) management?

Investors should contact their respective bank representatives to request one-on-one meetings with Coherus management during the conferences.